Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Ibrolipim

A lipoprotein lipase (LPL) activator with antihyperlipidemic activity. Activation of LDL by ibrolipim lowers plasma triglycerides, with a concomitant… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Objectives  The aim of the study was to elucidate the possible role and mechanism of NO‐1886 (ibrolipim, a lipoprotein lipase… Expand
2011
2011
BackgroundThe role of renal lipoprotein lipase (LPL) per se in kidney diseases is still controversial and obscure. The purpose of… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
2011
2011
OBJECTIVE Endothelial dysfunction is a key event in the onset and progression of atherosclerosis associated with diabetes… Expand
2010
2010
Aim:To determine the effects and potential mechanisms of ibrolipim on ATP-binding membrane cassette transporter A-1 (ABCA1) and… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
2006
2006
The mRNA levels of human cytochrome P450 (CYP)2Cs and CYP3As in primary cultures of freshly isolated human hepatocytes were… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
2006
2006
  • S. Kano, M. Doi
  • Metabolism: clinical and experimental
  • 2006
  • Corpus ID: 24186455
The synthetic compound NO-1886 (ibrolipim, [4-(4-bromo-2-cyano-phenylcarbamoyl)-benzyl]-phosphonic acid diethyl ester, CAS 133208… Expand
2005
2005
Although the lipoprotein lipase (LPL) activator NO-1886 shows antiobesity effects in high-fat-induced obese animals, the… Expand
2004
2004
In the present study, the effects on expression of cytochrome P450 (CYP1A1, CYP1A2, CYP3A4 and CYP3A5), carboxylesterase (CES1… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2004
2004
The synthetic compound NO-1886 (ibrolipim) is a lipoprotein lipase activator that has been proven to be highly effective in… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2003
2003
The lipoprotein lipase (LPL) activator NO-1886 (ibrolipim) has been shown to have potential benefits for the treatment of obesity… Expand